Nymox Pharma (NYMX) Nears Completion of NX03-0040 Post-Treatment Assessments in Prostate Cancer
Tweet Send to a Friend
Nymox Pharma (NASDAQ: NYMX) announced that participants in prostate cancer clinical trial NX03-0040 had neared completion of the study's 18 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
